Print Page      Close Window     

Investor Relations

Athenex is a global oncology focused biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, aiming to develop safer and more efficacious cancer medication.

Founded in 2003 and based in Buffalo, New York, our mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. We are focused on generating clinical candidates focused on oral delivery, and currently have 7 products including one currently in phase 3 and another for which we will soon commence a phase 3 study. Read more »

Stock Information
NASDAQ :  ATNX (Common Stock)
 - 0.11 (0.66%)
Data as of Feb 16, 2018 4:00 p.m. ET
Minimum 15 minute delay. Data provided by Nasdaq.
Refresh quote
Stock chart for: ATNX.O.  Currently trading at $16.66 with a 52 week high of $20.79 and a 52 week low of $11.21.